Journal article
Heritability and reliability of automatically segmented human hippocampal formation subregions
CD Whelan, DP Hibar, LS Van Velzen, AS Zannas, T Carrillo-Roa, KZ McMahon, G Prasad, S Kelly, J Faskowitz, G De Zubiracay, JE Iglesias, TGM Van Erp, T Frodl, NG Martin, MJ Wright, N Jahanshad, L Schmaal, PG Sämann, PM Thompson
Neuroimage | ACADEMIC PRESS INC ELSEVIER SCIENCE | Published : 2016
Open access
Abstract
The human hippocampal formation can be divided into a set of cytoarchitecturally and functionally distinct subregions, involved in different aspects of memory formation. Neuroanatomical disruptions within these subregions are associated with several debilitating brain disorders including Alzheimer's disease, major depression, schizophrenia, and bipolar disorder. Multi-center brain imaging consortia, such as the Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) consortium, are interested in studying disease effects on these subregions, and in the genetic factors that affect them. For large-scale studies, automated extraction and subsequent genomic association studies of these hi..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
This work was supported in part by a Consortium grant (U54 EB020403) from the NIH contributing to the Big Data to Knowledge (BD2K) Initiative, including the NIBIB. The study also received funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No 654911 (project "THALAMODEL"). Juan Eugenio Iglesias also acknowledges financial support from the Gipuzkoako Foru Aldundia (Fellows Gipuzkoa Program) and the Spanish Ministry of Economy and Competitiveness grant TEC2014-51882-P. Data collection and sharing for this project was funded in part by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.